Goncalves Marcus D, Iyengar Neil M
NYU Langone Health, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cell Metab. 2025 Feb 4;37(2):305-306. doi: 10.1016/j.cmet.2024.12.015.
Triple-negative breast cancer (TNBC) is highly glycolytic and lacks effective biomarkers for therapy response. The BREAKFAST trial showed that a fasting-mimicking diet (FMD) improved pathological complete response (pCR) rates to 56.6% compared to historical chemotherapy averages (30%-40%), with minimal severe adverse events. FMD's metabolic and immune-modulating effects warrant further study with immunotherapy.
三阴性乳腺癌（TNBC）具有高度糖酵解特性，且缺乏用于预测治疗反应的有效生物标志物。“早餐前试验”表明，与传统化疗平均水平（30%-40%）相比，模拟禁食饮食（FMD）可将病理完全缓解（pCR）率提高至56.6%，且严重不良事件极少。FMD的代谢和免疫调节作用值得与免疫疗法进行进一步研究。
